Gala­pa­gos rais­es $300M on the back of first PhI­II fil­go­tinib suc­cess; In­cyte push­es in­to PhI­II with top­i­cal Jakafi

→ Gala­pa­gos $GLPG wasn’t about to let the suc­cess of its first Phase III for fil­go­tinib — han­dled by lead part­ner Gilead — go by with­out a quick raise. The biotech gar­nered $300 mil­lion from the sale of its stock.

→ In­cyte $IN­CY says its Phase IIb study for a cream for­mu­la­tion of Jakafi (rux­oli­tinib) pro­duced promis­ing re­sults for pa­tients with atopic der­mati­tis. Re­searchers are now mov­ing ahead with a Phase III reg­is­tra­tion pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER